Cancer Diagnosis in Patients with Heart Failure: Epidemiology, Clinical Implications and Gaps in Knowledge
Pietro Ameri(Ospedale Policlinico San Martino), Carlo G. Tocchetti(Federico II University Hospital), Teresa López‐Fernández(Hospital Universitario La Paz), Gerasimos Filippatos(National and Kapodistrian University of Athens), Rudolf A. de Boer(Erasmus MC), Frank Ruschitska(University Hospital of Zurich), Stephan von Haehling(German Centre for Cardiovascular Research), Andrew J.S. Coats(The Heart Research Institute), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli"), Mitja Lainščak, Dimitrios Farmakis(National and Kapodistrian University of Athens), Alexander R. Lyon(Royal Brompton Hospital), Radek Pudil(Charles University), Marco Canepa(Ospedale Policlinico San Martino), Jutta Bergler‐Klein, Petar Seferović, Alain Cohen‐Solal(Inserm), Markus S. Anker(Humboldt-Universität zu Berlin), Thomas Suter(University of Bern), Yu. N. Belenkov(Sechenov University)
Cited by 183
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k